Garnet Anderson
#134,076
Most Influential Person Now
American biostatistician
Garnet Anderson's AcademicInfluence.com Rankings
Garnet Andersonmathematics Degrees
Mathematics
#6993
World Rank
#9592
Historical Rank
Statistics
#769
World Rank
#857
Historical Rank
Download Badge
Mathematics
Garnet Anderson's Degrees
- PhD Biostatistics University of Washington
- Masters Biostatistics University of Washington
Why Is Garnet Anderson Influential?
(Suggest an Edit or Addition)According to Wikipedia, Garnet Larae Anderson is an American biostatistician, known for her research on the health risks caused by side effects of postmenopausal hormone therapy, and more generally as one of the leading researchers in the Women's Health Initiative. She is a senior vice president at the Fred Hutchinson Cancer Research Center, where she directs the Public Health Sciences Division and holds the Fred Hutch 40th Anniversary Endowed Chair; she is also an affiliate professor of biostatistics at the University of Washington.
Garnet Anderson's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial (2002) (14635)
- Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. (2004) (4327)
- Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. (1998) (2280)
- Calcium plus vitamin D supplementation and the risk of fractures. (2006) (1778)
- Long-term exposure to air pollution and incidence of cardiovascular events in women. (2007) (1696)
- Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. (2013) (1108)
- Calcium plus vitamin D supplementation and the risk of colorectal cancer. (2006) (1003)
- Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. (2006) (873)
- Menarche, menopause, and breast cancer risk: individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies (2012) (745)
- Early detection: The case for early detection (2003) (703)
- The Women's Health Initiative recruitment methods and results. (2003) (701)
- Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. (2006) (695)
- Implementation of the Women's Health Initiative study design. (2003) (677)
- Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. (2006) (646)
- Ethnicity and breast cancer: factors influencing differences in incidence and outcome. (2005) (617)
- Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. (2006) (588)
- Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. (2010) (536)
- Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. (2003) (522)
- Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. (2009) (503)
- Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 (2009) (502)
- Overweight, Obesity, and Postmenopausal Invasive Breast Cancer Risk: A Secondary Analysis of the Women's Health Initiative Randomized Clinical Trials. (2015) (425)
- IARC monographs programme on the evaluation of carcinogenic risks to humans (2007) (393)
- Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. (2008) (373)
- Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. (2003) (368)
- Menopausal Hormone Therapy and Long-term All-Cause and Cause-Specific Mortality: The Women’s Health Initiative Randomized Trials (2017) (366)
- Breast cancer after use of estrogen plus progestin in postmenopausal women. (2009) (364)
- A cautionary note on inference for marginal regression models with longitudinal data and general correlated response data (1994) (362)
- Screening mammography: a missed clinical opportunity? Results of the NCI Breast Cancer Screening Consortium and National Health Interview Survey Studies. (1990) (358)
- Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence (2019) (350)
- Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. (2012) (335)
- Projecting individualized absolute invasive breast cancer risk in African American women. (2007) (306)
- Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial (2009) (290)
- Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. (2005) (284)
- Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study (2012) (275)
- 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial (2011) (255)
- Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. (2006) (249)
- Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. (2009) (239)
- A Prospective Evaluation of Insulin and Insulin-like Growth Factor-I as Risk Factors for Endometrial Cancer (2008) (238)
- Pancreatic cancer risk and ABO blood group alleles: results from the pancreatic cancer cohort consortium. (2010) (237)
- Selecting Differentially Expressed Genes from Microarray Experiments (2003) (233)
- Hypertension and Its Treatment in Postmenopausal Women: Baseline Data from the Women’s Health Initiative (2000) (232)
- Calcium plus vitamin D supplementation and mortality in postmenopausal women: the Women's Health Initiative calcium-vitamin D randomized controlled trial. (2009) (219)
- Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. (2007) (200)
- Oral bisphosphonate use and breast cancer incidence in postmenopausal women. (2010) (196)
- Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. (2007) (195)
- Multivitamin use and risk of cancer and cardiovascular disease in the Women's Health Initiative cohorts. (2009) (191)
- Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. (2013) (191)
- Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. (2006) (174)
- Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled trial. (2011) (172)
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. (2020) (170)
- Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. (2011) (170)
- Assessing Lead Time of Selected Ovarian Cancer Biomarkers: A Nested Case–Control Study (2010) (159)
- Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. (2011) (156)
- Genetic Determinants of Lipid Traits in Diverse Populations from the Population Architecture using Genomics and Epidemiology (PAGE) Study (2011) (153)
- Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. (2014) (152)
- Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. (2008) (151)
- Efficacy of exercise for menopausal symptoms: a randomized controlled trial (2013) (140)
- Changing concepts: Menopausal hormone therapy and breast cancer. (2012) (138)
- Bead-Based ELISA for Validation of Ovarian Cancer Early Detection Markers (2006) (137)
- Predicting risk of breast cancer in postmenopausal women by hormone receptor status. (2007) (135)
- Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. (2008) (129)
- Effects of a dietary intervention and weight change on vasomotor symptoms in the Women’s Health Initiative (2012) (127)
- Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701) (2013) (125)
- The women's health initiative: lessons learned. (2008) (116)
- Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. (2010) (114)
- Efficacy of yoga for vasomotor symptoms: a randomized controlled trial (2013) (105)
- Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy. (2013) (97)
- Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. (2008) (97)
- Influence of Ovarian Cancer Risk Status on the Diagnostic Performance of the Serum Biomarkers Mesothelin, HE4, and CA125 (2009) (95)
- A Prospective Evaluation of Endogenous Sex Hormone Levels and Colorectal Cancer Risk in Postmenopausal Women. (2015) (93)
- Approaches to monitoring the results of long-term disease prevention trials: Examples from the Women's Health Initiative (1996) (88)
- Obesity and the Risk for Premenopausal and Postmenopausal Breast Cancer (2012) (88)
- Menopausal quality of life: RCT of yoga, exercise, and omega-3 supplements. (2014) (87)
- Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. (2013) (86)
- Genome-wide association study identifies multiple risk loci for renal cell carcinoma (2017) (86)
- Effects of Personal Characteristics on Serum CA125, Mesothelin, and HE4 Levels in Healthy Postmenopausal Women at High-Risk for Ovarian Cancer (2008) (85)
- Statistical Issues Arising in the Women's Health Initiative (2005) (84)
- Low-Fat Dietary Pattern and Breast Cancer Mortality in the Women's Health Initiative Randomized Controlled Trial. (2017) (78)
- Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women (2016) (72)
- Body mass index, physical activity, and mortality in women diagnosed with ovarian cancer: results from the Women's Health Initiative. (2014) (69)
- Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial. (2016) (68)
- Heart rate variability, ambient particulate matter air pollution, and glucose homeostasis: the environmental epidemiology of arrhythmogenesis in the women's health initiative. (2009) (67)
- Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. (2013) (65)
- Effects of Pharmacologic and Nonpharmacologic Interventions on Insomnia Symptoms and Self-reported Sleep Quality in Women With Hot Flashes: A Pooled Analysis of Individual Participant Data From Four MsFLASH Trials (2018) (62)
- Efficacy of omega-3 for vasomotor symptoms treatment: a randomized controlled trial (2014) (61)
- Weight loss and breast cancer incidence in postmenopausal women (2018) (59)
- Both Light Intensity and Moderate‐to‐Vigorous Physical Activity Measured by Accelerometry Are Favorably Associated With Cardiometabolic Risk Factors in Older Women: The Objective Physical Activity and Cardiovascular Health (OPACH) Study (2017) (59)
- Low-fat dietary pattern and cardiovascular disease: results from the Women's Health Initiative randomized controlled trial. (2017) (58)
- Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. (2010) (57)
- Potential role of HE4 in multimodal screening for epithelial ovarian cancer. (2011) (56)
- Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women's health initiative randomized trials (2014) (55)
- Use of alternative time scales in Cox proportional hazard models: implications for time‐varying environmental exposures (2012) (55)
- Model misspecification in proportional hazards regression (1995) (53)
- Association of Low-Fat Dietary Pattern With Breast Cancer Overall Survival: A Secondary Analysis of the Women’s Health Initiative Randomized Clinical Trial (2018) (53)
- Women's Health Initiative (2014) (52)
- Dietary Modification and Breast Cancer Mortality: Long-Term Follow-Up of the Women's Health Initiative Randomized Trial. (2020) (52)
- The influence of obesity-related factors in the etiology of renal cell carcinoma—A mendelian randomization study (2019) (51)
- Hormonal Factors and Risks of Esophageal Squamous Cell Carcinoma and Adenocarcinoma in Postmenopausal Women (2011) (49)
- Two-stage experimental designs : early stopping with a negative result (1992) (49)
- Breast tenderness and breast cancer risk in the estrogen plus progestin and estrogen-alone women’s health initiative clinical trials (2012) (49)
- Methods for the design of vasomotor symptom trials: the Menopausal Strategies Finding Lasting Answers to Symptoms and Health network (2014) (49)
- Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative. (2013) (48)
- Effects of Blood Collection Conditions on Ovarian Cancer Serum Markers (2007) (48)
- The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormone-binding globulin levels in healthy postmenopausal women (2010) (44)
- Economic Return From the Women's Health Initiative Estrogen Plus Progestin Clinical Trial (2014) (44)
- Circulating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study (2016) (43)
- Inflammation and Oxidative Stress Markers and Esophageal Adenocarcinoma Incidence in a Barrett's Esophagus Cohort (2014) (43)
- Pooled Analysis of Six Pharmacologic and Nonpharmacologic Interventions for Vasomotor Symptoms (2015) (43)
- Ovarian Cancer Early Detection Claims Are Biased (2008) (42)
- Ambient Particulate Air Pollution and Ectopy—The Environmental Epidemiology of Arrhythmogenesis in Women's Health Initiative Study, 1999–2004 (2008) (42)
- Tubal sterilization and risk of subsequent hospital admission for menstrual disorders. (1992) (41)
- Ambient Fine Particulate Matter Exposure and Myocardial Ischemia in the Environmental Epidemiology of Arrhythmogenesis in the Women’s Health Initiative (EEAWHI) Study (2009) (39)
- Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. (2010) (39)
- Association of Powder Use in the Genital Area With Risk of Ovarian Cancer. (2020) (38)
- Tuba1 Sterilization and the Long‐Term Risk of Hysterectomy (1990) (38)
- Antioxidant supplement use in Women's Health Initiative participants. (2003) (37)
- Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. (2017) (35)
- The Role of Antioxidants and Vitamin A in Ovarian Cancer: Results From the Women's Health Initiative (2008) (35)
- Sex hormone levels and risk of breast cancer with estrogen plus progestin. (2013) (35)
- Breast Cancer and Menopausal Hormone Therapy by Race/Ethnicity and Body Mass Index. (2015) (34)
- Analgesic Use and Ovarian Cancer Risk: An Analysis in the Ovarian Cancer Cohort Consortium (2018) (34)
- The Women's Health Initiative (WHI) Life and Longevity After Cancer (LILAC) Study: Description and Baseline Characteristics of Participants (2017) (33)
- Menopausal hormone therapy and cancer: Changing clinical observations of target site specificity (2014) (33)
- Use of CA125 and HE4 Serum Markers to Predict Ovarian Cancer in Elevated-Risk Women (2014) (31)
- Effects of Yoga and Aerobic Exercise on Actigraphic Sleep Parameters in Menopausal Women with Hot Flashes. (2017) (31)
- Circulating Metabolites and Survival Among Patients With Pancreatic Cancer. (2016) (30)
- Use of Yeast-Secreted In vivo Biotinylated Recombinant Antibodies (Biobodies) in Bead-Based ELISA (2008) (30)
- Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage (2014) (30)
- Regression calibration in nutritional epidemiology: example of fat density and total energy in relationship to postmenopausal breast cancer. (2013) (29)
- Menopausal hormone therapy and breast cancer mortality: clinical implications (2015) (29)
- Menopausal Estrogen-Alone Therapy and Health Outcomes in Women With and Without Bilateral Oophorectomy (2019) (28)
- Low-Fat Dietary Pattern among Postmenopausal Women Influences Long-Term Cancer, Cardiovascular Disease, and Diabetes Outcomes (2019) (28)
- Postmenopausal Androgen Metabolism and Endometrial Cancer Risk in the Women's Health Initiative Observational Study. (2019) (27)
- Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects (2014) (27)
- Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. (2014) (27)
- Coronary heart disease and stroke with aromatase inhibitor, tamoxifen, and menopausal hormone therapy use. (2006) (27)
- Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women (2016) (26)
- Investigation of gene-by-sex interactions for lipid traits in diverse populations from the population architecture using genomics and epidemiology study (2013) (26)
- Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study (2017) (25)
- Breast tenderness after initiation of conjugated equine estrogens and mammographic density change (2012) (24)
- Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials (2007) (23)
- New-onset breast tenderness after initiation of estrogen plus progestin therapy and breast cancer risk. (2009) (22)
- Change in Physical Activity and Sitting Time After Myocardial Infarction and Mortality Among Postmenopausal Women in the Women's Health Initiative‐Observational Study (2017) (22)
- Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts (2018) (21)
- Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. (2015) (21)
- Oral bisphosphonate use and risk of postmenopausal endometrial cancer. (2015) (20)
- Application of blood concentration biomarkers in nutritional epidemiology: example of carotenoid and tocopherol intake in relation to chronic disease risk. (2019) (20)
- Reported Ovarian Cancer Screening Among a Population‐Based Sample in Washington State (2000) (19)
- The influence of time from menopause and mammography on hormone therapy-related breast cancer risk assessment. (2011) (19)
- Sex specific associations in genome wide association analysis of renal cell carcinoma (2019) (19)
- Coronary Artery Calcification (CAC) and Post‐Trial Cardiovascular Events and Mortality Within the Women's Health Initiative (WHI) Estrogen‐Alone Trial (2017) (18)
- Optimal cutoffs of obesity measures in relation to cancer risk in postmenopausal women in the Women's Health Initiative Study. (2015) (18)
- Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer. (2009) (17)
- Progestins and recurrence in breast cancer survivors. (2005) (17)
- The association of delay in curative intent treatment with survival among breast cancer patients: findings from the Women’s Health Initiative (2020) (17)
- Obesity and inflammation markers in relation to leukocyte telomere length in a cross-sectional study of persons with Barrett’s esophagus (2015) (17)
- Menopausal Hormone Therapy Influence on Breast Cancer Outcomes in the Women's Health Initiative. (2015) (17)
- Association of Prediagnostic Frailty, Change in Frailty Status, and Mortality After Cancer Diagnosis in the Women’s Health Initiative (2020) (17)
- Benefit/risk for adjuvant breast cancer therapy with tamoxifen or aromatase inhibitor use by age, and race/ethnicity (2015) (17)
- Use of administrative data to increase the practicality of clinical trials: Insights from the Women’s Health Initiative (2016) (17)
- Individually randomized intervention trials for disease prevention and control (1999) (16)
- Low-Fat Dietary Pattern and Cancer Mortality in the Women’s Health Initiative (WHI) Randomized Controlled Trial (2018) (15)
- Randomized Trial Evaluation of Benefits and Risks of Menopausal Hormone Therapy Among Women Aged 50-59. (2020) (15)
- Circulating androgens and postmenopausal ovarian cancer risk in the Women's Health Initiative Observational Study (2019) (14)
- Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET) (2013) (13)
- Methodological considerations for disentangling a risk factor's influence on disease incidence versus postdiagnosis survival: The example of obesity and breast and colorectal cancer mortality in the Women's Health Initiative (2017) (13)
- Sitting, physical activity, and serum oestrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study (2017) (13)
- Identifying post-menopausal women at elevated risk for epithelial ovarian cancer. (2015) (13)
- Estimation of the Correlation Between Nutrient Intake Measures Under Restricted Sampling (1999) (12)
- Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. (2009) (12)
- Overweight , Obesity , and Postmenopausal Invasive Breast Cancer Risk A Secondary Analysis of theWomen ’ s Health Initiative Randomized Clinical Trials (2015) (12)
- Risk Factor Burden, Heart Failure, and Survival in Women of Different Ethnic Groups: Insights From the Women’s Health Initiative (2018) (12)
- Embedding clinical interventions into observational studies. (2016) (12)
- Lights on MsFLASH: a review of contributions. (2020) (11)
- The association between heart failure and incident cancer in women: an analysis of the Women's Health Initiative (2020) (11)
- Abstract GS5-00: Long-term influence of estrogen plus progestin and estrogen alone use on breast cancer incidence: The Women's Health Initiative randomized trials (2020) (10)
- Forty‐year trends in menopausal hormone therapy use and breast cancer incidence among postmenopausal black and white women (2020) (10)
- Alcohol and oestrogen metabolites in postmenopausal women in the Women’s Health Initiative Observational Study (2017) (10)
- No evidence for increased risk (2010) (10)
- Estrogen metabolism in menopausal hormone users in the women's health initiative observational study: Does it differ between estrogen plus progestin and estrogen alone? (2018) (10)
- Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women’s Health Initiative Observational Study (2019) (9)
- Approached to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. (1996) (9)
- Randomized Trial Evaluation of the Benefits and Risks of Menopausal Hormone Therapy Among Women 50–59 Years of Age (2021) (9)
- Women’s Health Initiative Strong and Healthy Pragmatic Physical Activity Intervention Trial for Cardiovascular Disease Prevention: Design and Baseline Characteristics (2021) (9)
- Prentice et al. Respond to “How Far Can Epidemiologists Get with Statistical Adjustment?” (2005) (9)
- Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812) (2019) (8)
- Dual Outcome Intention-to-treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials. (2020) (8)
- AIR POLLUTION AND CARDIOVASCULAR DISEASE EVENTS IN THE WOMEN’S HEALTH INITIATIVE OBSERVATIONAL (WHI-OS) STUDY (2004) (8)
- Lifestyle and Cardiovascular Risk Factors Associated With Heart Failure Subtypes in Postmenopausal Breast Cancer Survivors (2022) (8)
- Prediagnosis social support, social integration, living status, and colorectal cancer mortality in postmenopausal women from the women's health initiative (2020) (8)
- Reanalysis of the Women's Health Initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit. (2005) (7)
- Migraine History, Nonsteroidal Anti-inflammatory Drug Use, and Risk of Postmenopausal Endometrial Cancer (2012) (7)
- Ovarian Cancer Biomarker Screening: Still Too Early to Tell (2010) (7)
- Comparing adaptive and non-adaptive algorithms for cancer early detection with novel biomarkers. (2006) (7)
- Post‐Genome‐Wide Association Study Challenges for Lipid Traits: Describing Age as a Modifier of Gene‐Lipid Associations in the Population Architecture Using Genomics and Epidemiology (PAGE) Study (2013) (7)
- Guideline‐concordant endometrial cancer treatment and survival in the Women's Health Initiative Life and Longevity After Cancer study (2020) (7)
- The Yet Unrealized Promise of Ovarian Cancer Screening. (2018) (7)
- Effect of cocoa flavanol supplementation for the prevention of cardiovascular disease events: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial (2022) (7)
- Nutritional epidemiology and the Women's Health Initiative: a review. (2021) (6)
- Determinants, circumstances and consequences of injurious falls among older women living in the community (2020) (6)
- Intellectual Equipoise and Challenges: Accruing Patients With Advanced Cancer to a Trial Randomizing to Surgical or Nonsurgical Management (SWOG S1316) (2020) (6)
- The Women's Health Initiative: Rationale, Design and Progress Report (1999) (6)
- Factors Associated With New‐Onset Depression Following Ischemic Stroke: The Women's Health Initiative (2017) (6)
- Combined estrogen-progestogen contraceptives (2007) (6)
- Ambient air pollution and lung cancer risk among never-smokers in the Women's Health Initiative (2019) (6)
- The Impact of the COVID-19 Pandemic on Older Women in the Women’s Health Initiative (2022) (6)
- Can dietary self-reports usefully complement blood concentrations for estimation of micronutrient intake and chronic disease associations? (2020) (5)
- Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630 (2016) (5)
- Design and baseline characteristics of participants in the COcoa Supplement and Multivitamin Outcomes Study (COSMOS). (2022) (5)
- Breast Cancer and Nonsteroidal Anti-Inflammatory Drugs : Prospective Results from the Women ’ s Health Initiative 1 (2003) (5)
- Reliable evidence from placebo-controlled, randomized, clinical trials for menopausal hormone therapy's influence on incidence and deaths from breast cancer (2015) (5)
- Combined estrogen-progestogen menopausal therapy (2007) (5)
- Estrogen Plus Progestin and Lung Cancer in Postmenopausal Women (2010) (5)
- Low-fat dietary pattern and long-term breast cancer incidence and mortality: The Women’s Health Initiative randomized clinical trial. (2019) (5)
- Recommendation to use exact P-values in biomarker discovery research in place of approximate P-values. (2018) (4)
- A Randomised Trial of empiric 14-day Triple, five-day Concomitant, and ten-day Sequential Therapies for Helicobacter pylori in Seven Latin American Sites (2016) (4)
- Hormone Therapy and Risk of Gynecologic Cancers [2] (multiple letters) (2004) (4)
- Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer (2022) (4)
- A Randomized Trial Comparing 14-Day Triple, 10-Day Sequential, and 5-Day Concomitant Therapy to Eradicate Helicobacter pylori in Seven Latin American Populations (2011) (4)
- Calcium plus vitamin D supplementation and the risk of fractures: Commentary (2006) (3)
- Randomized phase II study of docetaxel plus vandetanib (D+V) versus docetaxel followed by vandetanib (D-V) in patients with persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (OC): SWOG S0904. (2012) (3)
- Contributions of the Women's Health Initiative to Cardiovascular Research: JACC State-of-the-Art Review. (2022) (3)
- Mediation by differential DNA methylation of known associations between single nucleotide polymorphisms and bladder cancer risk (2020) (3)
- Low-Fat Diet and Cardiovascular Disease—Reply (2006) (3)
- 1. ACCF/AHA. (2007). Clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation, 115, 402- (2011) (3)
- Obesity, Height, and Serum Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study (2021) (3)
- Associations Between Changes in Loneliness and Social Connections, and Mental Health During the COVID-19 Pandemic: The Women’s Health Initiative (2021) (3)
- An Environmental Scan of Biopsychosocial and Clinical Variables in Cohort Studies of Cancer Survivors (2019) (3)
- Multivitamins in the prevention of cancer and cardiovascular disease: The COSMOS randomized clinical trial. (2022) (3)
- Randomized double-blind placebo-controlled biomarker modulation study of vitamin d in premenopausal women at high risk for breast cancer (SWOG S0812). (2018) (2)
- Abstract GS5-07: Weight change in postmenopausal women and breast cancer risk in the women's health initiative observational study (2018) (2)
- 1046 Predictors of Success of Helicobacter pylori Eradication Treatment in a Multicentric Randomized Clinical Trial (SWOG S0701) in Latin America (2012) (2)
- Women's health initiative view of estrogen avoidance and all-cause mortality. (2013) (2)
- A Statistical Perspective on Prevention Trials: A View from the Women’s Health Initiative (2013) (2)
- Prediction of disability-free survival in healthy older people (2022) (2)
- Su1673 H. pylori Recurrence One Year After Eradication Treatment in a Population Randomized Trial (SWOG S0701) in Seven Latin American Sites (2012) (2)
- Abstract CT043: Low-fat dietary pattern and breast cancer mortality in the Women's Health Initiative (WHI) randomized trial (2016) (2)
- Breast cancer outcome and estrogen plus progestin use in postmenopausal women. (2010) (2)
- Hormone Therapy and Risk of Gynecologic Cancers—Reply (2004) (2)
- Narrowing of racial disparities in breast cancer incidence: insights from menopausal hormone therapy study findings. (2016) (1)
- FOUR AUTHORS REPLY (2008) (1)
- Concerns about published data from the estrogen-progestin (HT) arm of the WHI. (2005) (1)
- JAMA Peer Reviewers in 2021. (2022) (1)
- JAMA Peer Reviewers in 2019. (2020) (1)
- Su1677 Risk Factors for Helicobacter pylori Infection in Six Latin American Countries (SWOG Trial S0701) (2012) (1)
- Association Between Obesity and Postmenopausal Breast Cancer Risk-Reply. (2015) (1)
- Abstract S5-04: Low-fat dietary pattern and breast cancer overall survival in the women's health initiative dietary modification randomized controlled trial (2017) (1)
- Lung cancer and hormone replacement therapy – Authors' reply (2010) (1)
- Long-term Trajectories of Physical Function Decline in Women With and Without Cancer. (2023) (1)
- Health State Utilities Values For Post-Menopausal Women From The Women's Health Initiative Estrogen+Progestin Clincial Trial (2013) (1)
- Incidental genetic findings in randomized clinical trials: recommendations from the Genomics and Randomized Trials Network (GARNET) (2013) (1)
- JAMA Peer Reviewers in 2018. (2019) (1)
- Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial (2022) (1)
- Multivitamins in the prevention of cancer and cardiovascular disease: the COcoa Supplement and Multivitamin Outcomes Study (COSMOS) randomized clinical trial (2022) (1)
- Conduct of the Women's Health Initiative randomised trial evaluating estrogen plus progestin: implications for breast cancer findings (2013) (1)
- Abstract 13885: Phenotyping Risk Profiles for Heart Failure With Preserved and Reduced Ejection Fraction Among Breast Cancer Survivors (2020) (1)
- Abstract 3471: Ambient particulate air pollution and ectopy - The Environmental Epidemiology of Arrhythmogenesis in WHI (EEAWHI), 1999 2004 (2007) (1)
- Reply: Reanalysis of the data—science at its best and always informative (2006) (1)
- Abstract 4296: Serum estrogen and estrogen metabolites and smoking among postmenopausal women in the Women's Health Initiative Observational Study (2016) (1)
- The association of predicted resting energy expenditure with risk of breast cancer among postmenopausal women in the Women's Health Initiative cohort. (2022) (1)
- Abstract 1031: Estrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy (2012) (1)
- Corrigendum re "Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma" [Eur Urol 2017;72:747-54]. (2018) (1)
- Incorrect Author Academic Degree and Incomplete Name. (2015) (0)
- Abstract 2214: The genomic landscape of lung cancer in post-menopausal never-smoker women (2021) (0)
- Ovarian Cancer Early Detection Claims Are Biased. Authors' reply (2008) (0)
- Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials (2020) (0)
- Thanks to authors and peer reviewers (2008) (0)
- Abstract OT1-15-01: SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE) (2023) (0)
- Reply to Ramírez PC and Diaz-Quijano FA (AJCN-D-22-00631). (2022) (0)
- Issue Information (2018) (0)
- Practice of Epidemiology Regression Calibration in Nutritional Epidemiology : Example of Fat Density and Total Energy in Relationship to Postmenopausal Breast Cancer (2013) (0)
- Breast Cancer in Postmenopausal Women After Hormone Therapy—Reply (2011) (0)
- Analgesic use and circulating estrogens, androgens, and their metabolites in the Women's Health Initiative Observational Study. (2021) (0)
- Estrogen plus progestin (E+P) and breast cancer incidence and mortality. (2012) (0)
- Association of Powder Use in the Genital Area With Risk of Ovarian Cancer (2020) (0)
- Abstract PO029: Oral contraceptive use and postmenopausal sex steroid hormone metabolism (2021) (0)
- Low-fat dietary pattern and all cancer mortality in the Women's Health Initiative (WHI) randomized trial. (2018) (0)
- Reply to The Women's Health Initiative; hormone replacement therapy; and Surveillance, Epidemiology, and End Results data (2020) (0)
- 590 One-Year Effectiveness and Costs of Six Alternative H. pylori Test/Treat and Retest/Retreat Strategies Using Triple, Concomitant or Sequential Drug Regimens in Seven Latin American Sites (SWOG Trial S0701) (2012) (0)
- 60P Association between food frequency questionnaire estimates and serum concentrations of β-carotene, retinol, retinyl palmitate, and α-tocopherol among participants in the caret lung cancer chemoprevention trial (1994) (0)
- Low-fat diet and cardiovascular disease. Authors' reply (2006) (0)
- Predicting risk of estrogen receptor positive breast cancers in postmenopausal women (2007) (0)
- Epidemiology of Helicobacter pylori infection in six Latin American countries (SWOG Trial S0701) (2012) (0)
- Usefulness of Echocardiography in Infants With Supraventricular Tachycardia (2003) (0)
- A comprehensive evaluation of breast cancer treatment delays by race among Women's Health Initiative participants. (2018) (0)
- Prentice et al. Respond to “Studying Co-Occurrence of Multiple Outcomes” (2020) (0)
- "Preventing breast cancer in postmenopausal women by achievable diet modification: A missed opportunity in public health policy" (Dayal HH and Kalia A, The Breast 2010; 19: 309-311) (2011) (0)
- Lifestyle Factors and Risk of Breast Cancer: A Review of Randomized Trial Findings (2010) (0)
- Response: Re: Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer (2009) (0)
- Breast cancer after stopping estrogen plus progestin in postmenopausal women in the women's health initiative. (2009) (0)
- Mortality Associated with Healthy Eating Index Components and an Empirical-scores Healthy Eating Index in a Cohort of Postmenopausal Women. (2022) (0)
- Treatment of Helicobacter pylori in Latin America – Authors' reply (2012) (0)
- Menopausal hormone therapy and breast cancer by body mass index (BMI) and African ancestry. (2014) (0)
- Th-W59:1 Postmenopausal hormone therapy-lessons from the women's health initiative (2006) (0)
- Abstract IA20: Biomarkers for risk prediction, screening, and early diagnostics. (2016) (0)
- Abstract P1-13-02: Benefit/risk of invasive breast cancer adjuvant tamoxifen or aromatase inhibitor use by age, race/ethnicity, and co-morbidity (2013) (0)
- Mortality Associated with Healthy Eating Index Components and an Empirical-Scores Healthy Eating Index in a Cohort of Postmenopausal Women. (2022) (0)
- Rejoinder (2005) (0)
- Investigation of gene-by-sex interactions for lipid traits in diverse populations from the population architecture using genomics and epidemiology study (2013) (0)
- Abstract 5880: Diabetes incidence after obesity-related cancer diagnosis and survival in the women’s health initiative (2022) (0)
- Anthropometric measures and serum estrogen metabolism in postmenopausal women: the Women’s Health Initiative Observational Study (2017) (0)
- Abstract ED01-02: Methodologic considerations for large-scale prevention trials: Lessons from the Women's Health Initiative (2012) (0)
- Abstract OT3-3-02: Phase IIB randomized double-blind placebo-controlled biomarker modulation study of high dose vitamin D in premenopausal women at high-risk for breast cancer: SWOG S0812 (2013) (0)
- Women's Health Initiative: Statistical Aspects and Selected Early Results (2005) (0)
- Histamine H2 Receptor Antagonists and Heart Failure Risk in Postmenopausal Women: The Women’s Health Initiative (2022) (0)
- Intraindividual variability over time in plasma biomarkers of inflammation and effects of long-term storage (2014) (0)
- Somatic mutation but not aneuploidy differentiates lung cancer in never-smokers and smokers (2023) (0)
- Abstract 050: Fine-mapping and Bioinformatics Characterization of QT Interval Loci in African Americans: The Population Architecture Using Genomics and Epidemiology (PAGE) Study (2012) (0)
- Hormone Therapy for the Prevention of Chronic Conditions in Postmenopausal Persons. (2023) (0)
- Rare loss of function variants in candidate genes and risk of colorectal cancer (2018) (0)
- Non-small cell lung cancer and estrogen plus progestin use in postmenopausal women in the Women's Health Initiative randomized clinical trial. (2009) (0)
- A24 The Genome-Wide Mutational Landscape of Lung Cancer in Never-Smokers: The Women’s Health Initiative (WHI) Cohort (2020) (0)
- Helicobacter pylori Seropositivity, ABO Blood Type, and Pancreatic Cancer Risk from 5 Prospective Cohorts. (2023) (0)
- Response to Commentary on 'Dual Outcome Intention-To-Treat Analyses in the Women's Health Initiative Randomized Controlled Hormone Therapy Trials'. (2020) (0)
- Magnets for Patients With Heel Pain (2017) (0)
- Thanks to Reviewers (2007) (0)
- Title: Sex Specific Associations in Genome Wide Association Analysis of Renal Cell Carcinoma (2019) (0)
- Sex specific associations in genome wide association analysis of renal cell carcinoma (2019) (0)
- Thanks to reviewers in 2010 (2010) (0)
- Abstract LB-170: Breast cancer incidence and hormone therapy use before and after the Women’s Health Initiative (WHI) estrogen (E) plus progestin (P) trial by race/ethnicity (2019) (0)
- Emerging Common Strategies to Reduce Breast and Endometrial Cancer Risk (2017) (0)
- An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012. (2013) (0)
- Recreational Physical Activity, Sitting, and Androgen Metabolism among Postmenopausal Women in the Women's Health Initiative Observational Study (2021) (0)
- Abstract 4237: Estrogen metabolism in menopausal hormone users: Does it differ between estrogen plus progestin and estrogen alone users in the Women’s Health Initiative Observational Study (2017) (0)
- A Statistical Perspective on Prevention Trials: A View from the Women’s Health Initiative (2013) (0)
- Title Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer : SWOG S 9630 (2016) (0)
- SWOG S0820/PACES (Preventing Adenomas of the Colon with Eflornithine and Sulindac): A randomized, double-blind, placebo-controlled phase III clinical trial. (2015) (0)
- The 2010 North American Menopause Society position statement on hormone therapy goes beyond the available evidence. (2012) (0)
- Hormone therapy and risk of gynecologic cancers. Authors' reply (2004) (0)
- Abstract P5-15-02: Withdrawn (2018) (0)
- JAMA Peer Reviewers in 2018. (2019) (0)
- Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts (2018) (0)
- Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects (2014) (0)
This paper list is powered by the following services:
Other Resources About Garnet Anderson
What Schools Are Affiliated With Garnet Anderson?
Garnet Anderson is affiliated with the following schools:
